ArticleFrontiers in oncology2020
Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.Cancer medicine · 2026Article
- Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation.Frontiers in immunology · 2025Review
- Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases.Annals of hematology · 2025Article
- A Single-Center Experience: Integrated Management in Primary Central Nervous System Lymphoma.Cureus · 2024Article
- Surgical Considerations in Treating Central Nervous System Lymphomas: A Case Series of 11 Patients.Current oncology (Toronto, Ont.) · 2024Article
- C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients.Neurosurgical review · 2023Article
- The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma.Clinical and experimental medicine · 2023Article
- Conditional survival of elderly primary central nervous system lymphoma.Journal of cancer research and clinical oncology · 2023Article
- Non-cancer-specific survival in patients with primary central nervous system lymphoma: A multi-center cohort study.Frontiers in oncology · 2023Article
- Progress of radiological‑pathological workflows in the differential diagnosis between primary central nervous system lymphoma and high‑grade glioma (Review).Oncology reports · 2023Article
- A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis.Frontiers in oncology · 2023Article
- Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas.Frontiers in oncology · 2022Article
- Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population-based analysis.Annals of translational medicine · 2021Article
- Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).International journal of oncology · 2021Review
- Recent Progress on Primary Central Nervous System Lymphoma-From Bench to Bedside.Frontiers in oncology · 2021Review
- Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy.Frontiers in oncology · 2021Article
- Elevated neutrophil-to-lymphocyte ratio as a prognostic factor in primary central nervous system lymphoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substantial controversy still exists regarding the use of surgical excision in the treatment of primary central nervous system lymphoma (PCNSL). This study was aimed to evaluate the survival benefit of surgical excision in PCNSL patients based on a US population. Using the Surveillance, Epidemiology, and End Results (SEER) Program database, a total of 3,543 PCNSL patients were identified from 2000 to 2014 for analysis. Surgical excision was accessed via Kaplan-Meier and multivariate Cox regression survival analyses. Coarsened exact matching (CEM) analysis was additionally employed to intensify our findings. Finally, we found that surgical excision was significantly associated with increased survival over no surgery/biopsy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.